Critics	NNS	B
of	IN	I
harm	NN	O
reduction	NN	O
contend	VB	O
that	IN	O
it	PRP	B
appears	VBZ	O
to	TO	B
condone	VB	O
and	CC	B
even	RB	O
facilitate	VB	O
behaviours	NNS	O
that	WDT	O
are	VBP	B
dangerous	JJ	O
,	,	B
socially	RB	O
destabilizing	VBG	O
or	CC	B
considered	VBN	I
immoral	JJ	O
.	.	O

For	IN	O
these	DT	B
reasons	NNS	I
,	,	B
harm	NN	O
reduction	NN	O
has	VBZ	B
been	VBN	I
very	RB	B
controversial	JJ	O
in	IN	O
the	DT	B
United	NNP	O
States	NNP	O
,	,	B
where	WRB	O
it	PRP	B
has	VBZ	I
met	VBN	O
more	JJR	B
resistance	NN	O
than	IN	O
in	IN	O
Europe	NNP	O
,	,	B
Canada	NNP	O
,	,	B
Australia	NNP	O
and	CC	B
New	NNP	O
Zealand	NNP	O
.	.	O

In	IN	O
the	DT	B
United	NNP	O
States	NNP	O
,	,	B
debate	NN	O
about	IN	O
harm	NN	O
reduction	NN	O
is	VBZ	B
very	RB	I
polarized	JJ	O
.	.	O

Advocates	NNS	O
are	VBP	B
often	RB	I
characterized	VBN	O
as	IN	O
"	``	B
pro	JJ	O
-	``	B
drug	NN	O
"	''	B
.	.	O

Opponents	NNS	O
of	IN	B
harm	NN	O
reduction	NN	O
are	VBP	B
often	RB	I
criticised	VBN	O
for	IN	O
ignoring	VBG	O
the	DT	B
realities	NNS	O
and	CC	B
circumstances	NNS	O
of	IN	B
addictions	NNS	O
,	,	B
disregarding	VBG	O
scientific	JJ	O
evidence	NN	B
,	,	I
marginalizing	VBG	O
the	DT	B
basic	JJ	O
human	JJ	O
rights	NNS	O
of	IN	B
affected	VBN	O
persons	NNS	O
,	,	B
and	CC	I
responding	VBG	O
from	IN	O
a	DT	B
position	NN	O
of	IN	B
"	``	I
moral	JJ	O
panic	NN	O
"	''	B
.	.	O

